Companies › Ionis Pharmaceuticals
12 active drug programs in 18 registered trials: 11 Phase 3, 6 Phase 1, 1 Phase 2; Neurology, Metabolic and endocrine, Psychiatry, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Donidalorsen | – | Phase 3 | Hereditary Angioedema; Hereditary Angioedema (HAE) | Dec 2026 |
| Olezarsen Apolipoprotein C-III mRNA antisense inhibitor | APOC3 | Phase 3 | Severe Hypertriglyceridemia; Familial Chylomicronemia Syndrome | Mar 2027 |
| obudanersen (ION582) antisense oligonucleotide targeting paternal UBE3A mRNA to restore maternal UBE3A expressi | UBE3A | Phase 3 | Angelman Syndrome | Aug 2027 |
| ION363 Antisense oligonucleotide targeting FUS mRNA | FUS | Phase 3 | Amyotrophic Lateral Sclerosis | Mar 2028 |
| Eplontersen Transthyretin mRNA antisense inhibitor | TTR | Phase 3 | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Aug 2029 |
| zilganersen (ION373) Antisense oligonucleotide targeting GFAP mRNA | GFAP | Phase 3 | Alexander Disease | Jul 2034 |
| ION775 APOC3 antisense oligonucleotide | – | Phase 2 | Hypertriglyceridemia | Sep 2027 |
| ION717 | – | Phase 1 | Prion Disease | Apr 2027 |
| ION440 Antisense oligonucleotide targeting MECP2 | MECP2 | Phase 1 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | Sep 2027 |
| ION464 unclear - antisense oligonucleotide (likely, given Ionis Pharmaceuticals' focus) | – | Phase 1 | Multiple System Atrophy | Sep 2027 |
| ION356 Antisense oligonucleotide targeting PLP1 | – | Phase 1 | Pelizaeus-Merzbacher Disease | Jun 2028 |
| ION337 SCN1A antisense oligonucleotide | – | Phase 1 | Dravet Syndrome | Dec 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05392114 | Donidalorsen | Phase 3 | Hereditary Angioedema | Immunology | Dec 2026 |
| NCT05681351 | Olezarsen | Phase 3 | Severe Hypertriglyceridemia | Metabolic and endocrine | Mar 2027 |
| NCT06153966 | ION717 | Phase 1 | Prion Disease | Infectious disease | Apr 2027 |
| NCT05185843 | Olezarsen | Phase 3 | Familial Chylomicronemia Syndrome | Metabolic and endocrine | Jun 2027 |
| NCT06914609 | obudanersen (ION582) | Phase 3 | Angelman Syndrome | Other | Aug 2027 |
| NCT06430385 | ION440 | Phase 1 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | Psychiatry | Sep 2027 |
| NCT07604974 | ION775 | Phase 2 | Hypertriglyceridemia | Metabolic and endocrine | Sep 2027 |
| NCT04165486 | ION464 | Phase 1 | Multiple System Atrophy | Neurology | Sep 2027 |
| NCT05130450 | Olezarsen | Phase 3 | Familial Chylomicronemia Syndrome | Metabolic and endocrine | Feb 2028 |
| NCT04768972 | ION363 | Phase 3 | Amyotrophic Lateral Sclerosis | Neurology | Mar 2028 |
| NCT07782827 | obudanersen (ION582) | Phase 3 | Angelman Syndrome | Other | May 2028 |
| NCT06150716 | ION356 | Phase 1 | Pelizaeus-Merzbacher Disease | Metabolic and endocrine | Jun 2028 |
| NCT05127226 | obudanersen (ION582) | Phase 1 | Angelman Syndrome | Other | Mar 2029 |
| NCT07298447 | Donidalorsen | Phase 3 | Hereditary Angioedema (HAE) | Immunology | Jun 2029 |
| NCT05071300 | Eplontersen | Phase 3 | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Neurology | Aug 2029 |
| NCT07727538 | Olezarsen | Phase 3 | Familial Chylomicronemia Syndrome | Metabolic and endocrine | Aug 2030 |
| NCT07531745 | ION337 | Phase 1 | Dravet Syndrome | Neurology | Dec 2030 |
| NCT04849741 | zilganersen (ION373) | Phase 3 | Alexander Disease | Neurology | Jul 2034 |
Cash and short-term investments of $1.9bn on 2026-09-30; operating cash outflow about $546m a year; runway about 41 months at that burn, to Mar 2030; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Arrowhead Pharmaceuticals Biogen Praxis Precision Medicines Alnylam Pharmaceuticals Amylyx Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.